Abstract word count: 250/250

Main text word count: 3,260/3,500 (Introduction: 459, Methods: 824, Results: 687,

Discussion: 1290) + 29/30 references

Supplement word count: 1,769 + 20 references

Figures: 3 # Tables: 3

Supplemental Tables: 14 # Supplemental Figures: 4

Psychotic-like experiences and polygenic liability in the ABCD Study®

Nicole R. Karcher, PhD¹, Sarah E. Paul, BA², Emma C. Johnson, PhD¹, Alexander S. Hatoum, PhD¹, David AA Baranger, PhD³, Arpana Agrawal, PhD¹, Wesley K. Thompson, PhD⁴, Deanna M. Barch, PhD^{1,2}, Ryan Bogdan, PhD²

Author's note: Correspondence concerning this article should be addressed to Nicole R. Karcher, Ph.D., Department of Psychiatry, One Brookings Drive, Campus Box 1125, Washington University, St. Louis, MO 63130 email: nkarcher@wustl.edu

Department of Psychiatry, Washington University School of Medicine, St. Louis, MO

² Department of Psychological and Brain Sciences, Washington University, St. Louis, MO

³ Department of Psychiatry, University of Pittsburgh, PA

⁴ Division of Biostatistics, Department of Family Medicine and Public Health, University of California, San Diego

Abstract

Background: Psychotic-like experiences (PLEs) during childhood are harbingers for severe psychopathology, including psychotic disorders, and neurodevelopmental impairments in adolescence and adulthood.

Methods: Data from children of genomically-confirmed European ancestries (n=4,650; ages 9-10; 46.8% female) who completed the baseline Adolescent Brain Cognitive Development[®] Study session were used to assess whether PLEs (i.e., both total and the presence of significantly distressing) are associated with polygenic scores (PGS) related to psychopathology (i.e., schizophrenia [SCZ], educational attainment [EDU], psychiatric cross-disorder risk [CROSS], PLEs). We also assessed whether variability in global and region indices of brain structure (i.e., volume, cortical thickness, surface area) as well as behaviors proximal to PGS (e.g., cognition for EDU) indirectly linked PGS to PLEs using mediational models.

Findings: EDU and CROSS PGS were associated with total and significantly distressing PLEs (all $\%\Delta R^2$ s=0.202-0.660%; ps<0.002). Significantly distressing PLEs were also associated with higher SCZ and PLEs PGS (both $\%\Delta R^2$ =0.120-0.171%; ps<0.02). Global brain volume metrics and cognition indirectly linked EDU PGS to PLEs (proportion mediated: 3.33-32.22%).

Interpretation: Total and distressing PLEs were associated with genomic risk indices associated with broad spectrum psychopathology risk (i.e., EDU and CROSS PGS). Significantly distressing PLEs were associated with genomic risk for psychosis (i.e., SCZ, PLEs). Global brain volume metrics and PGS-proximal behaviors represent promising putative intermediary phenotypes that may contribute to genomic risk for

psychopathology. Broadly, polygenic scores derived from genome-wide association

studies of adult samples can generalize to indices of psychopathology risk among

children and aid the identification of putative neural and behavioral intermediaries of

risk.

Funding: National Institute of Health

Introduction

Psychotic-like experiences (PLEs) are nonclinical schizophrenia spectrum symptoms that include perceptual abnormalities and mild delusional thoughts. They commonly occur in children (~10% of children and adolescents) and are considered a dimensional, transdiagnostic marker of significant psychopathology risk (e.g., odds ratio ~ three), including conversion to adult psychotic disorders in some children. The adverse mental health prognosis of children with PLEs, even beyond those who eventually develop schizophrenia, has inspired efforts to identify children at risk for their development and improve our understanding of PLE etiology to ultimately facilitate advances in prevention and treatment.

Building upon twin work documenting the moderate heritability of PLEs, genome-wide association studies (GWASs) have shown that PLEs are highly polygenic, much like other complex behavioral and biological phenotypes.^{e.g.,3} Results from well-powered "discovery" GWASs may be projected onto individuals in an independent sample by averaging common variants - weighted by GWAS effect size and number of risk alleles present - across the genome to generate polygenic scores (PGS) that represent an individual's genomic predisposition for the "discovery" GWAS phenotype.⁴ In contrast to initial evidence reporting null associations between schizophrenia PGSs and adolescent PLEs using a relatively low-powered "discovery" GWAS (cases n=9,394⁵),^{e.g.,6} recent work leveraging results from a large GWAS of schizophrenia (cases n=36,989⁷) has generally linked schizophrenia PGSs to PLEs during adolescence and adulthood (e.g., ages 15-19).^{e.g.,8} Further, other work has found associations between later-life PLEs and

both schizophrenia and mood disorder PGSs.³ However, aside from these studies generally examining associations between schizophrenia PGSs and PLEs, no studies, to our knowledge, have examined whether associations are present during childhood and whether PGSs for other phenotypes are associated with PLEs.

Given evidence that PLEs may reflect non-specific indicators of general psychopathology vulnerability that share common genetic risk with a wide range of psychopathologies and related phenotypes (e.g., schizophrenia, depression, ADHD, cognition),^{3,9} genomic vulnerability to broad spectrum psychopathology may confer risk for PLEs in childhood. Further, based on epidemiological studies linking psychosis spectrum symptoms to neurodevelopmental impairments including reduced educational attainment and lower cognition,¹⁰ polygenic propensity for educational attainment (i.e., which is genetically correlated with cognitive functioning and risk-taking),¹¹ may also confer vulnerability for childhood PLEs. Finally, emerging evidence linking PLEs to variation in brain structure, including lower global brain volume,¹² suggest that brain structure may indirectly link genomic risk to PLE expression.¹³

Using data from genomically-confirmed non-Hispanic children (aged nine-to-ten) of European ancestries who completed the baseline session of the ongoing Adolescent Brain Cognitive Development[®] (ABCD) study (n=4,650), we examined whether PLEs are associated with PGSs for schizophrenia (SCZ), psychiatric cross-disorder risk (CROSS), PLEs, and educational attainment (EDU). Finally, we probed whether variability in brain structure (i.e., volume, surface area, cortical thickness) and/or

proximal PGS behaviors (e.g., cognition for EDU) indirectly associate polygenic scores to PLEs.

Methods

Participants

A sample of 11,875 individuals was obtained from the ABCD Study[®] (Data Release 2.0.1), a large-scale ongoing longitudinal study of children recruited from 22 research sites across the United States (see Supplement for study-wide exclusion criteria).¹⁴ ABCD Study[®] data were accessed from the National Institutes of Mental Health Data Archive (see Acknowledgments). Participants who did not pass quality control metrics and those who were not of genomically-confirmed European ancestries were removed leaving a final analytic sample of 4,650 (46.8% female; mean age= 9.93±0.04 years; Supplement).

Measures

All measures are described in detail within the Supplement.

Psychotic-like Experiences. The dimensional total score of the 21-item child-reported Prodromal Questionnaire-Brief Child Version (PQ-BC)¹⁵ was used to assess PLEs. Further, we generated a binary metric based upon endorsement of at least one significantly distressing PLE (i.e., rating a PLE between three-to-five on a five-point scale, n=972; Table 1).

Proximal EDU and CROSS PGS Behaviors. Total cognition composite scores assessed using the National Institutes of Health Toolbox Cognitive Battery¹⁶ and a general psychopathology factor¹⁷ created using the Child Behavior Checklist,¹⁸ served as proximal behavioral measures of EDU PGS and CROSS PGS, respectively.

Brain Structure. The following global and regional structural MRI metrics were examined: *global:* intracranial, total cortical, and total subcortical volume; total surface area; and total cortical thickness; *regional:* 34 bilateral Desikan cortical regions for surface area, thickness, and volume, as well as 22 Freesurfer segmentation subcortical volume regions (including all 12 bilateral subcortical segmentations). T1- and T2-weighted structural scans (1mm isotropic) were acquired using 3T scanners (either Siemens, General Electric, or Phillips) with 32-channel head coils.

Polygenic Scores. Summary statistics from the most well-powered "discovery" GWASs of SCZ (N=36,989 cases + 113,075 controls),⁷ CROSS (N=232,964 cases [anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depressive disorder, obsessive-compulsive disorder, schizophrenia, and Tourette's syndrome] + 494,162 controls),⁹ PLEs (N=127,966),³ and EDU (N=766,345)¹¹ were used to generate PGS (n=4) within the ABCD Study® dataset. PGS were generated using polygenic risk scores-continuous shrinkage (PRS-CS),²⁰ which uses a Bayesian regression framework to include all SNPs in PGS calculation by placing a continuous shrinkage prior on SNP effect sizes; simulation studies show that

PRS-CS outperforms other PGS methods.²⁰ Analyses using traditional p-value clumping and thresholding produced results consistent with PRS-CS (Supplemental Tables 1-2).

Statistical Analyses

Individual values on continuous predictor and outcome variables were Winsorized to ±3 SD to minimize the influence of extreme values. All analyses nested data with random intercepts for site (n=22) and family (n=3,874; siblings n=616). The following covariates were included in all analyses: age, sex, genotyping batch, and the first ten ancestrally-informative PCs (described in the Supplement). We used ComBat harmonization (https://github.com/ ncullen93/neuroCombat) to estimate and remove scanner model effects from MRI measures. Further, scanner type (i.e., Siemens, Philips, GE) was included as an additional covariate in all brain structure analyses; regional structural analyses further included intracranial volume. Financial adversity and highest parental/caregiver education (described in the Supplement) were included as additional covariates in supplemental analyses. Benjamini-Hochberg False Discovery Rate (FDR) correction was used to adjust for multiple comparisons.

First, we estimated associations between SCZ, PLE, CROSS, and EDU PGS with each PLE metric (i.e., dimensional total score and binary significantly distressing PLEs). FDR correction was used to account for the four PGSs tested. For CROSS and EDU, *post-hoc* HLMs examined models including measured behaviors most proximal to the PGS, to examine the extent to which available measured outcomes proximal to PGSs

¹ Given the strong correlation (r=.66) between PLE total score and PLE significant distress group, we did not adjust for multiple testing for these 2 phenotypes.

accounted for these associations (e.g., the extent to which cognition accounted for the association between EDU PGS and PLE). Second, we estimated associations between reported PLEs and MRI-derived brain structure phenotypes (i.e., total and regional surface area, cortical volume, cortical thickness, and subcortical volume). FDR was used to adjust for multiple testing (i.e., five tests for global MRI metrics, 102 tests for bilateral and average cortical metrics [i.e., Cortical Thickness, Cortical Surface Area, Cortical Volume, and 45 tests for bilateral and average subcortical volume). For any brain structure phenotypes associated with reported PLEs, models subsequently examined the association with each PGS that was associated with reported PLE metrics. Third, we conducted a series of parallel mediation analyses to estimate indirect associations (boot strapped 95% C.I.s) between PGS and reported PLEs through each of the brain structure phenotypes associated with reported PLEs and proximal PGS behaviors entered in parallel. The Ime4²¹ (Imer for total PLEs, glmer for binary significantly distress PLEs) and lavaan²² R packages were used to conduct hierarchical linear mixed effects regression and nested mediation analyses, respectively.

Role of the funding source

The funding source had no role in the writing of the manuscript or the decision to submit it for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

Polygenic Scores and Psychotic-like Experiences

In our sample (n=4,650), 55.33% (n=2,573) of children endorsed at least one reported PLE and 20.90% (n=972) endorsed at least one significantly distressing PLE. *Total PLEs* were associated with higher CROSS and lower EDU PGS (all $|\beta s| > 0.045$, all ps<0.002, p_{FDR}s<0.004; % $\Delta R^2s>0.20\%$), but not SCZ or PLE PGS (all $|\beta s| \le 0.015$, all ps>0.29; Table 2; Figure 1). When included in the same model, CROSS (all $\beta s>0.042$, all ps<0.004) and EDU (all $\beta s>-0.069$, all ps=2.96 x 10⁻⁰⁶) PGS both remained associated with reported PLEs. Endorsement of *Significantly Distressing PLEs* was associated with higher SCZ, PLE, and CROSS PGS as well as lower EDU PGS (all $|\beta s|>0.032$, all ps≤0.02, p_{FDR}s<0.02; % $\Delta R^2s\ge0.12\%$; Table 2; Figure 1). All associations remained similar when further accounting for financial adversity and parental/caregiver education (p_{FDR}s<0.03), or when computing PGS using a traditional clustering and thresholding approach (Supplemental Tables 1-2).

Consideration of Proximal EDU and CROSS PGS Behaviors: Cognition and General Psychopathology. Measured cognition was negatively associated with *Total PLEs* and endorsement of *Significantly Distressing PLEs* and positively associated with EDU PGS ($|\beta s| \ge 0.131$, all ps<2.00 x 10⁻¹⁶, % $\Delta R^2 s \ge 1.55\%$; Supplemental Table 3; Supplemental Figures 1-2). Cognitive performance accounted for 32.3-32.8% of the association between EDU PGS and PLE metrics (Supplemental Table 4), though associations between EDU PGS and reported PLE metrics remained, even when considering cognition ($\beta s > -0.047$, ps<0.002; % $\Delta R^2 s \ge 0.58\%$; Supplemental Table 5).

The general psychopathology factor was positively associated with Total PLEs and

endorsement of Significantly Distressing PLEs as well as CROSS PGS (all βs≥0.057, all

ps≤0.001, %∆R²s>0.29%; Supplemental Table 3; Supplemental Figures 1-2). General

psychopathology accounted for between 11.3-17.8% of the association between

CROSS PGS and reported PLEs, though these remained associated with each other

(Total: β =0.034, p=0.048, ΔR^2 =0.24%; Significantly Distressing PLEs: β =0.056,

p=0.002, $\%\Delta R^2$ =0.72%; Supplemental Table 5).

Psychotic-like Experiences and Brain Structure

Greater reported PLEs (both *Total* and endorsement of *Significantly Distressing PLEs*)

were associated with lower intracranial volume, total cortical volume, total subcortical

volume, total cortical thickness, and total surface area (all βs<-0.032, all ps<0.04, all

 p_{EDR} s<0.04; all % ΔR^2 s>0.06; Table 2; Figure 2). When examining individual structural

MRI regions for volume, surface area, and thickness, greater Total PLEs were

associated with lower average and right inferior parietal cortical thickness (both \$s>-

0.067, both ps< 5.53×10^{-4} , both p_{FDR}s=0.03; both % ΔR^2 s>0.21%; Table 2; Figure 2). No

11

other individual structural MRI regions passed FDR correction (see Supplemental

Tables 6-13).

Mediation Analyses

Educational Attainment Polygenic Scores. EDU PGS were associated with brain

structure phenotypes associated with reported PLEs (i.e., intracranial volume, total

Schizophrenia and Cross Disorder Polygenic Scores. SCZ and PLE PGS were not associated with reported PLE-related global or regional brain structure measures (Supplemental Table 14). Although total surface area was associated with CROSS PGS (β =0.037, p=0.004, p_{FDR}=0.02; % Δ R²=0.11; Table 3), it did not mediate associations

between CROSS PGS and reported PLEs (95% CI: -0.005 to 0.000; Supplement). No other reported PLE-related brain phenotypes were associated with CROSS PGS (Table 3).

Discussion

Here, we show that psychotic-like experiences (PLEs) in middle childhood (n=4,650) are associated with GWAS-derived indices of polygenic risk (all %ΔR²s=0.120-0.660%) as well as potential putative intermediary neural and behavioral phenotypes that may partially underlie these associations (all $\%\Delta R^2$ s=0.062-2.85%). Genomic liability for educational attainment higher psychopathology (i.e., lower and psychopathology, schizophrenia, late-life PLEs) were associated with more PLEs among children (Figure 1). There was divergence in the strength of associations across phenotypic definitions of PLEs (i.e., broad-total PLEs, versus severe-presence of significantly distressing PLEs). Specifically, genomic liability for broad spectrum psychopathology (CROSS PGS) and educational attainment (EDU PGS) were associated with both PLEs measures; SCZ and late-life PLE PGS were associated only with the presence of significantly distressing PLEs. Broadly, this divergence mirrors phenotypic observations that PLEs may portend broad psychopathology vulnerability, 1 while severe expressions of PLEs may foreshadow psychosis risk.²³ However, the direction of association and estimated effect size, despite differences in significance, were similar across phenotypic PLE measures (i.e., broad and severe; Figure 1). Finally, reported PLEs were associated with lower global (e.g., intracranial volume) and regional (i.e., inferior parietal thickness was associated with broad PLEs) brain structure

metrics (Figure 2), with evidence that lower volume (i.e., ICV, total cortical and total subcortical) indirectly links EDU PGS to reported PLEs alongside cognition (Figure 3). Collectively, these results show that polygenic scores derived from GWAS of adult samples can generalize to indices of risk among children. Because PLEs can develop in children with a negative family history of psychotic disorders, they may, eventually, prove useful indices of risk for psychopathology beyond familial history. As larger GWASs of both precise and broad phenotypes continue to emerge, polygenic risk indices may help target individuals for preventative therapies (e.g., cognitive behavioral interventions) and further help disarticulate the biological and behavioral mechanisms underlying psychiatric risk that may ultimately contribute to advances in treatment and nosology.

Polygenic Propensity for Education Attainment

Polygenic scores for lower educational attainment were the most robust PGS predictor of both total PLEs and significantly distressing PLEs. These findings suggest that prior reports linking EDU PGS to severe psychosis among clinical patients²⁴ may generalize to earlier markers of psychosis spectrum symptoms during middle childhood. That cognition accounted for a large portion (28.57-32.22% of variance) of the association between educational attainment and reported PLEs aligns with evidence that premorbid cognition prospectively predicts PLEs and psychopathology, including schizophrenia,¹⁰ and suggests that such vulnerability may be partially genomic in origin. However, other work has failed to find a strong genetic correlation between later-life PLEs and intelligence;³ it is possible that genomic associations between PLEs and cognition may

later life (e.g., PLEs related to cognitive decline and/or dementia²⁵).

Supportive of neurodevelopmental models of psychosis spectrum disorders which posit that brain differences underlie cognition-related vulnerability for schizophrenia, we found evidence that brain volume accounts for a portion of the association between educational attainment PGS and reported PLEs (3.22-8.79%; Supplemental Table 4; Figure 3). However, given that these neural metrics are less proximal to educational attainment polygenic scores than cognition, it is unsurprising that associations for cognition were larger than associations for brain structure. PLEs and global volume reductions are consistent with previous research examining volumetric alterations. That lower global volume may indirectly link educational attainment PGS and reported PLEs is consistent with the notion that genomic liability for lower cognitive functioning may be associated with altered neural maturational processes, which may contribute to the development or maintenance of psychosis spectrum symptoms. The province of the psychosis spectrum symptoms.

General Psychopathology, Schizophrenia, and PLE Polygenic Risk

Genomic liability for broad spectrum psychopathology (i.e., CROSS PGS) was associated with broadly defined as well as severe PLEs, while polygenic scores for SCZ and PLEs were only associated with severe PLEs. These findings add to developing evidence from phenotypic research that PLEs represent transdiagnostic harbingers of broad-spectrum psychopathology as opposed to psychosis-specific risk, while more

severe forms of PLEs that elicit distress may be more uniquely associated with psychosis-specific liability. 1,2 This is consistent with prior research finding stronger associations between SCZ PGS and distressing PLEs; however, this previous work also found associations between later-life broadly defined PLEs and SCZ PGS.3 These findings also align with evidence that polygenic and phenotypic psychopathology associations may be more non-specific in middle childhood and potentially become increasingly specific with increased severity (e.g., with more clinically significant PLEs) and/or maturation (e.g., in adolescence). 28 We did not find strong evidence of associations between broadly defined PLEs with polygenic risk for later life PLEs, although there were associations between later life PLEs PGS and more severe PLEs. It is entirely possible that PLEs during *middle/late life* (the basis of the PLE PGS score used here) are somewhat etiologically distinct from broadly defined childhood PLEs. Further, it is important to consider that the CROSS disorder PGS was generated using GWASs of eight psychopathologies (i.e., schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, autism spectrum disorder, obsessive-compulsive disorder, anorexia nervosa, Tourette syndrome), of which psychosis spectrum disorders (i.e., schizophrenia and bipolar disorder) were the most well-powered. Thus, CROSS PGS effects are potentially driven by schizophrenia and its pleiotropy. Alongside evidence of similar effect size estimates across both PLE measures within PGS, it is plausible that with better powered discovery GWAS and target samples, PLEs defined broadly and with regard to distress will show similar relationships.

Limitations

It is important to consider major limitations of this study while interpreting these findings. First, the generalizability of these findings are limited, as we restricted analyses to those of genomically-confirmed European ancestries due to the sample compositions of the discovery GWASs and evidence that polygenic risk does not translate across ancestries.²⁹ Second, reported PLEs were assessed only via self-report and were not corroborated with clinical interview. However, initial evidence from the ABCD Study® suggests that PLEs can be validly assessed using the PQ-BC in a middle childhood sample, as evidenced by associations with family history of psychosis, impaired cognition, and other indices of psychopathology. 15 Third, and consistent with expectations and prior PGS studies, the effects reported are generally small (for associations with reported PLEs, |βs|<.09) and suggest that PGS in their current form have little direct applied clinical utility for childhood PLEs. As "discovery" GWASs continue to grow, it will be critical to acquire additional GWASs datasets across development, including in childhood, to examine genetic correlations for the same phenotype across ages as well as differential associations with psychopathology and structural neural metrics. Fourth, our mediational analyses are non-experimental and based on cross-sectional data. While these analyses provide empirical evidence consistent with putative gene-brain-behavior mechanisms underlying childhood PLE risk, they should not be interpreted by themselves to imply causation. For example, it remains plausible that the presence of PLEs could influence brain structure. Lastly, it is important to note that the GWASs have differential power to detect effects (e.g., the EDU GWAS was based on 766,345 individuals, versus the PLEs GWAS was based on

127,966 individuals). These differences in power present challenges for interpreting across different PGSs.

Conclusions

Broadly, GWAS-based polygenic scores are associated with indices of psychopathology and PLEs during middle childhood. Polygenic liability to educational attainment was the most robust predictor of both broadly defined PLEs as well as severe PLEs, and there was evidence that these associations may be partially mediated by cognitive performance and brain structure. Polygenic score associations mirrored phenotypic evidence that broadly defined PLEs are associated with severe broad-spectrum psychopathology risk while more severe PLEs may index psychosis liability. Taken together, the current study documents that GWAS-derived polygenic scores index psychopathology and psychosis vulnerability in children. The PGSs do not have current clinical utility but support the identification of putative intermediate biological and behavioral mechanisms through which genomic risk for psychopathology emerges.

Contributors

NRK, RB, and DMB developed the research questions. NRK, SEP, ECJ, and ASH conducted analyses. RB, DMB, AA, WKT, and DAAB provided critical revision of the manuscript for important intellectual content. NRK, RB, SEP, and ECJ had full access to all data and take responsibility for the integrity of the data and accuracy of analyses. All authors have approved the final version of the manuscript.

Declaration of interests

We declare no competing interests.

Acknowledgments

Data used in the preparation of this article were obtained from the Adolescent Brain Cognitive Development (ABCD) Study (https://abcdstudy.org), held in the NIMH Data Archive (NDA). This is a multisite, longitudinal study designed to recruit more than 11,500 children age 9-10 and follow them over 10 years into early adulthood. The ABCD Study is supported by the National Institutes of Health and additional federal partners under award numbers U01DA041022, U01DA041025, U01DA041028, U01DA041048, U01DA041089, U01DA041093, U01DA041106, U01DA041117, U01DA041120, U01DA041134, U01DA041148, U01DA041156, U01DA041174, U24DA041123, and U24DA041147. A full list of supporters is available at https://abcdstudy.org/nih-collaborators. A listing of participating sites and a complete listing of the study investigators can be found at https://abcdstudy.org/principal-investigators.html. ABCD consortium investigators designed and implemented the study and/or provided data but did not necessarily participate in analysis or writing of this report. This manuscript reflects the views of the authors and may not reflect the opinions or views of the NIH or ABCD consortium investigators.

The ABCD data repository grows and changes over time. The ABCD data used in this report came from DOI 10.15154/1460410.

The authors thank Drs. Michelini and Kotov for the creation of the general psychopathology scores.

This work was supported by National Institute of Health grants U01 DA041120 (DMB), MH014677 (NRK), MH109532, DA032573 (AA), F32 AA027435 (ECJ), T32-DA007261 (ASH), R01-AG045231, R01-HD083614, R01-AG052564, R21-AA027827, R01-DA046224 (RB).

Financial Disclosures

The authors report no biomedical financial interests or potential conflicts of interest.

References

- 1. Healy C, Brannigan R, Dooley N, et al. Childhood and adolescent psychotic experiences and risk of mental disorder: a systematic review and meta-analysis. *Psychol Med* 2019; **49**(10): 1589-99.
- 2. Poulton R, Caspi A, Moffitt TE, Cannon M, Murray R, Harrington H. Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. *Arch Gen Psychiatry* 2000; **57**(11): 1053-8.
- 3. Legge SE, Jones HJ, Kendall KM, et al. Association of Genetic Liability to Psychotic Experiences With Neuropsychotic Disorders and Traits. *JAMA Psychiatry* 2019; **76**(12): 1256-65.
- 4. Bogdan R, Baranger DA, Agrawal A. Polygenic risk scores in clinical psychology: bridging genomic risk to individual differences. *Annual review of clinical psychology* 2018; **14**: 119-57.
- 5. Genome-wide association study identifies five new schizophrenia loci. *Nature genetics* 2011; **43**(10): 969-76.
- 6. Zammit S, Hamshere M, Dwyer S, et al. A population-based study of genetic variation and psychotic experiences in adolescents. *Schizophr Bull* 2014; **40**(6): 1254-62.
- 7. Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 2014; **511**(7510): 421-7.
- 8. Pain O, Dudbridge F, Cardno AG, et al. Genome-wide analysis of adolescent psychotic-like experiences shows genetic overlap with psychiatric disorders. *American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics* 2018; **177**(4): 416-25.
- 9. Lee PH, Anttila V, Won H, et al. Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. *Cell* 2019; **179**: 1469-82.
- 10. Sheffield JM, Karcher NR, Barch DM. Cognitive Deficits in Psychotic Disorders: A Lifespan Perspective. *Neuropsychology review* 2018.
- 11. Lee JJ, Wedow R, Okbay A, et al. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. *Nature genetics* 2018; **50**(8): 1112-21.
- 12. Satterthwaite TD, Wolf DH, Calkins ME, et al. Structural Brain Abnormalities in Youth With Psychosis Spectrum Symptoms. *JAMA Psychiatry* 2016; **73**(5): 515-24.
- 13. Alloza C, Blesa-Cábez M, Bastin ME, et al. Psychotic-like experiences, polygenic risk scores for schizophrenia, and structural properties of the salience, default mode, and central-executive networks in healthy participants from UK Biobank. *Translational psychiatry* 2020; **10**(1): 122.
- 14. Barch DM, Albaugh MD, Avenevoli S, et al. Special Issue: Adolescent Brain and Cognitive Development Demographic, Physical and Mental Health Assessments in the Adolescent Brain and Cognitive Development Study: Rationale and Description. *Developmental Cognitive Neuroscience*: In press.
- 15. Karcher NR, Barch DM, Avenevoli S, et al. Assessment of the Prodromal Questionnaire-Brief Child Version for Measurement of Self-reported Psychoticlike Experiences in Childhood. *JAMA Psychiatry* 2018; **75**(8): 853-61.
- 16. Weintraub S, Dikmen SS, Heaton RK, et al. Cognition assessment using the NIH Toolbox. *Neurology* 2013; **80**(11 Suppl 3): S54-64.

- 17. Michelini G, Barch DM, Tian Y, Watson D, Klein DN, Kotov R. Delineating and validating higher-order dimensions of psychopathology in the Adolescent Brain Cognitive Development (ABCD) study. *Translational psychiatry* 2019; **9**(1): 261.
- 18. Achenbach TM. The Achenbach System of Emprically Based Assessment (ASEBA): Development, Findings, Theory and Applications. Burlington, VT: University of Vermont Research Center for Children, Youth, and Families; 2009.
- 19. Hagler Jr DJ, Hatton S, Cornejo MD, et al. Image processing and analysis methods for the Adolescent Brain Cognitive Development Study. *NeuroImage* 2019; **202**: 116091.
- 20. Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nature communications* 2019; **10**(1): 1-10.
- 21. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. *arXiv preprint arXiv:14065823* 2014.
- 22. Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. Mediation: R package for causal mediation analysis. 2014.
- 23. Zammit S, Kounali D, Cannon M, et al. Psychotic experiences and psychotic disorders at age 18 in relation to psychotic experiences at age 12 in a longitudinal population-based cohort study. *Am J Psychiatry* 2013; **170**(7): 742-50.
- 24. Dwyer DB, Kalman JL, Budde M, et al. An Investigation of Psychosis Subgroups With Prognostic Validation and Exploration of Genetic Underpinnings: The PsyCourse Study. *JAMA Psychiatry* 2020.
- 25. Connors MH, Ames D, Woodward M, Brodaty H. Psychosis and Clinical Outcomes in Alzheimer Disease: A Longitudinal Study. *Am J Geriatr Psychiatry* 2018; **26**(3): 304-13.
- 26. Bogdan R, Baranger DAA, Agrawal A. Polygenic Risk Scores in Clinical Psychology: Bridging Genomic Risk to Individual Differences. *Annual review of clinical psychology* 2018; **14**: 119-57.
- 27. Lesh TA, Niendam TA, Minzenberg MJ, Carter CS. Cognitive control deficits in schizophrenia: mechanisms and meaning. *Neuropsychopharmacology* 2011; **36**(1): 316-38.
- 28. Riglin L, Thapar AK, Leppert B, et al. Using Genetics to Examine a General Liability to Childhood Psychopathology. *Behav Genet* 2019.
- 29. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. *Nature genetics* 2019; **51**(4): 584-91.

Table 1. Sample Characteristics

	Significantly Di				
Variable (N)	No Significantly Distressing PLEs (N=3678)	Endorsed Significantly Distressing PLEs (N=972)	Total Sample (N=4650)		
Age in years (4650)	9.948 ± 7.525	9.882 ± 7.351	9.934 ± 7.495		
Sex, % female (4650)	1722 (46.8%)	454 (46.7%)	2176 (46.8%)		
Scanner Type (4532)					
Siemens, %	2408 (65.5%)	576 (59.3%)	2984 (64.2%)		
Philips, %	481 (13.1%)	125 (12.9%)	606 (13.0%)		
General Electric, %	694 (18.9%)	247 (25.4%)	942 (20.3%)		
PLEs (4649)					
Total PLEs	1.110 ± 1.875	6.180 ± 3.686	2.170 ± 3.142		
Distressing PLEs	1.675 ± 2.940	16.701 ± 10.036	4.816 ± 8.076		
Significantly Distressing PLEs	0±0	2.158 ± 1.470	0.451 ± 1.105		
PGS (4650)	7				
SCZ	$3.532 \times 10^{-7} \pm 1.860 \times 10^{-7}$	$3.724 \times 10^{-7} \pm 1.846 \times 10^{-7}$	$3.572 \times 10^{-7} \pm 1.855 \times 10^{-7}$		
EDU	-1.459x10 ⁻⁷ ± 9.251x10 ⁻⁸	-1.639x10 ⁻⁷ ± 9.212x10 ⁻⁸	-1.497x10 ⁻⁷ ± 9.271x10 ⁻⁸		
PLE	-1.810x10 ⁻⁶ ± 6.374x10 ⁻⁷	-1.820x10 ⁻⁶ ± 6.552x10 ⁻⁷	-1.808x10 ⁻⁶ ± 6.411x10 ⁻⁷		
CROSS	$3.029 \times 10^{-7} \pm 8.535 \times 10^{-8}$	$3.181 \times 10^{-7} \pm 8.484 \times 10^{-8}$	$3.061 \times 10^{-7} \pm 8.546 \times 10^{-8}$		
Global Brain Metrics					
Intracranial Volume (3914)	1.560x10 ⁻⁶ ± 1.303x10 ⁻⁵	1.535x10 ⁻⁶ ± 1.478x10 ⁻⁵	1.555x10 ⁻⁶ ± 1.414x10 ⁻⁵		
Total Cortical Volume (4520)	6.138x10 ⁻⁵ ± 5.280x10 ⁻⁴	6.066x10 ⁻⁵ ± 5.448x10 ⁻⁴	6.123x10 ⁻⁵ ± 5.323x10 ⁻⁴		
Total Subcortical Volume (4520)	6.145x10 ⁻⁴ ± 4.755x10 ⁻³	6.061x10 ⁻⁴ ± 4.882x10 ⁻³	6.128x10 ⁻⁴ ± 4.793x10 ⁻³		
Total Cortical Thickness (4520)	2.799 ± 0.106	2.785 ± 0.109	2.796 ± 0.107		
Total Surface Area (4520)	1.905x10 ⁻⁵ ± 1.747x10 ⁻⁴	1.892x10 ⁻⁵ ± 1.761x10 ⁻⁴	1.902x10 ⁻⁵ ± 1.750x10 ⁻⁴		
Proximal PGS Behaviors					
Cognitive Scores (4580)	89.353 ± 7.785	86.774 ± 7.968	88.814 ± 7.893		
General Psychopathology Scores (3120)	-0.012 ± 0.869	0.292 ± 0.938	0.050 ± 0.892		

Abbreviations: PLEs=psychotic-like experiences; PGS=polygenic scores; SCZ=Schizophrenia; EDU=Educational Attainment; CROSS=Cross Disorder.

Table 2. Associa	Total PLEs							s Group	Group			
	b [95% CI]	β	t	р	p fdr	$%\Delta R^{2}$	OR [95% CI]	β	Z	р	p fdr	%ΔR ²
PGS												
Schizophrenia	2.62x10 ⁵ [2.25x10 ⁵ ,7.50x10 ⁵]	0.015	1.054	.29	.36	0.022%	1.110 [1.030,1.200]	0.038	2.736	.006	.008	0.171%
Educational Attainment	-2.76x10 ⁶ [3.74x10 ⁶ ,-1.79x10 ⁶]	-0.081	-5.561	2.85 x10 ⁻⁸	1.14 x10 ⁻⁷	0.660%	0.825 [0.766,0.890]	-0.072	-4.988	6.09x 10 ⁻⁷	2.44x10 ⁻⁶	0.587%
PLEs	6.21x10 ⁵ [6.93x10 ⁵ ,1.94x10 ⁶]	0.013	0.925	.36	.36	0.019%	1.090 [1.010,1.170]	0.032	2.259	.02	.02	0.120%
Cross Disorder	1.67x10 ⁶ [6.18x10 ⁵ ,2.73x10]	0.045	3.099	.002	.004	0.202%	1.190 [1.110,1.290]	0.066	4.600	4.23x 10 ⁻⁶	8.46x10 ⁻⁶	0.505%
Neural Metrics												<u> </u>
Global Metrics	4.40.40-6						0.050					0.372
Intracranial Volume	-1.48x10 ⁻⁶ [-2.36x10 ⁻⁶ ,-5.93x10 ⁻⁷]	-0.065	-3.274	.001	.001	0.062%	0.858 [0.774,0.950]	-0.055	-2.935	.003	.004	u u
Total Cortical Volume	-4.03 x10 ⁻⁶ [-5.96x10 ⁻⁶ , -2.10x10 ⁻⁶]	-0.067	-4.091	4.37 x10 ⁻⁵	2.19x10 ⁻⁴	0.380%	0.847 [0.779,0.921]	-0.061	-3.865	1.11x 10 ⁻⁴	2.78x10 ⁻⁴	0.332
Total Subcortical Volume	-3.83x10 ⁻⁵ [-6.00x10 ⁻⁵ , -1.67x10 ⁻⁵]	-0.057	-3.466	5.33 x10 ⁻⁴	1.25x10 ⁻³	0.271%	0.825 [0.757,0.898]	-0.070	-4.201	9.78x 10 ⁻⁶	4.89x10 ⁻⁵	0.442
Total Cortical Thickness	-1.21 [-2.192,-0.235]	-0.041	-2.430	.02	.02	0.161%	0.915 [0.841,0.997]	-0.032	-1.868	.04	.04	0.069
Total Surface Area	-1.08x10 ⁻⁵ [-1.71x10 ⁻⁵ , -4.54x10 ⁻⁶]	-0.058	-3.374	7.47 x10 ⁻⁴	1.25x10 ⁻³	0.247%	0.858 [0.785,0.938]	-0.057	-3.231	7.74x 10 ⁻⁴	.001	0.2419
Regional Metrics												
Average Inferior Parietal Thickness	-1.47 [-2.301, -0.646]	-0.069	-3.490	4.89 x10 ⁻⁴	.03	0.210%	0.886 [0.7950,0.998]	-0.043	-2.185	.03	.27	0.122%
Right Inferior Parietal Thickness	-1.35 [-2.117, -0.585]	-0.067	-3.457	5.53 x10 ⁻⁴	.03	0.233%	0.888 [0.803,0.982] Deta coefficient; 9 R ² =percentage ch ding the predicto	-0.045	-2.324	.02	.27	0.1389

	Ed	Cross Disorder PGS										
	b [95% CI]	β	t	р	p_{FDR}	%ΔR²	b [95% CI]	β	t	р	p_{FDR}	%ΔR²
Global Structural Metrics												%ΔR ² 0.005% 0.040%
Intracranial Volume	1.08x10 ¹¹ [7.06x10 ¹⁰ , 1.46x10 ¹¹]	0.073	5.640	1.82x 10 ⁻⁸	3.03x 10 ⁻⁸	0.705%	1.98x10 ¹⁰ [-2.09x10 ¹⁰ , 6.05x10 ¹⁰]	0.012	0.953	.34	.43	0.005%
Total Cortical Volume	4.93x10 ¹⁰ [3.43x10 ¹⁰ , 6.43x10 ¹⁰]	0.088	6.440	1.32x 10 ⁻¹⁰	6.60x 10 ⁻¹⁰	0.825%	1.43x10 ¹⁰ [-1.97x10 ⁹ , 3.06x10 ¹⁰]	0.023	1.723	.09	.21	0.040%
Total Subcortical Volume	2.91x10 ⁹ [1.57x10 ⁹ , 4.24x10 ⁹]	0.058	4.257	2.12 x10 ⁻⁵	2.65x 10 ⁻⁵	0.353%	4.83x10 ⁸ [-9.67x10 ⁸ , 1.93x10 ⁹]	0.009	0.653	.51	.51	0.000%
Total Cortical Thickness	1.59x10 ⁴ [-1.39x10 ⁴ , 4.58 x10 ⁴]	0.014	1.045	.30	.30	0.066%	-2.35x10 ⁴ [-5.58x10 ⁴ , 8.80x10 ⁴]	-0.019	-1.426	.15	.26	0.025%
Total Surface Area	1.44x10 ¹⁰ [9.82x10 ⁹ , 1.90x10 ¹⁰]	0.079	6.139	9.04 x10 ⁻¹⁰	2.26x 10 ⁻⁹	0.568%	7.25x10 ⁹ [2.26x10 ⁹ , 1.22x10 ¹⁰]	0.037	2.849	.004	.02	0.1109
Regional Metrics												0.110%
Average Inferior Parietal Thickness	6.71x10 ³ [-3.15x10 ⁴ , 4.49x10 ⁴]	0.004	0.344	.73	.73	0.026%	-1.16x10 ⁴ [-5.30x10 ⁴ , 2.98x10 ⁴]	-0.007	-0.548	.58	.58	0.005%
Right Inferior Parietal Thickness	-1.14x10 ⁴ [-5.24x10 ⁴ , 2.95x10 ⁴]	-0.007	-0.547	.58	.73	0.024%	-2.18x10 ⁴ [-6.61x10 ⁴ , 2.25x10 ⁴]	-0.012	-0.964	.34	.58	0.003%




Figure 1. Proportion of variance explained (R-squared) by each of the different PGS scores (SCZ=Schizophrenia; EDU =Educational Attainment; PLE=Psychotic-like experiences; CROSS=Cross Disorder) for both Total and Significantly Distressing PLEs. Error bars represent the 95% confidence interval, * p_{FDR} <0.05, ** p_{FDR} <0.01, *** p_{FDR} <0.001.




Figure 2. Proportion of variance explained (R-squared) by each of the significant global (intracranial volume, total cortical volume, total subcortical volume, surface area) and regional (inferior parietal thickness) MRI metrics for both Total and Significantly Distressing PLEs. Error bars represent the 95% confidence interval, * p_{FDR} <0.05, ** p_{FDR} <0.01, *** p_{FDR} <0.001.




Figure 3. Depiction of a series of parallel mediation models, examining evidence for each neural metric ((A) intracranial, (B) cortical volume, (C) subcortical volume, and (D) surface area) indirectly linking Educational Attainment PGS (EDU PGS) and total psychotic-like experiences (Total PLEs) alongside cognitive performance in parallel. Covariates (i.e., age, sex, genotyping batch, and the first ten ancestrally-informative PCs) were included in all models. Each parallel mediation model depiction includes unstandardized regression coefficients, showing the association between EDU PGS, each neural metric and cognition, and Total PLEs.